Current Strategies in the Evaluation and Management of Cocaine-Induced Chest Pain

Authors:

Abstract
With each successive year, the number of Emergency Department (ED) visits related to illicit drug abuse has progressively increased. Cocaine is the most common illegal drug to cause a visit to the ED. Cocaine use results in a variety of pathophysiological changes with regards to the cardiovascular system, such as constriction of coronary vessels, dysfunction of vascular endothelium, decreased aortic elasticity, hemodynamic disruptions, a hypercoagulable state, and direct toxicity to myocardial as well as vascular tissue. The clinical course of patients with cocaine-induced chest pain is often challenging, and electrocardiographic findings can be potentially misleading in terms of diagnosing a myocardial infarction. In addition, there is no current satisfactory study regarding outcomes of use of various pharmacological drug therapies to manage cocaine associated chest pain. At present, calcium channel blockers and nitroglycerin are two pharmacological agents which are advocated as first-line drugs for cocaine-induced chest pain management, while the role of labetalol has been controversial and warrants further investigation. We performed an extensive search of available literature through a large number of scholarly articles previously published and listed on Index Medicus. In this review we put forward a concise summary of the current approach to a patient presenting to the ED with cocaine associated chest pain, and management of the clinical scenario. The purpose of this review is to summarize the understanding of cocaine's cardiovascular pathophysiology, and examine the current approach for proper evaluation and management of cocaine-induced chest pain.

This publication has 88 references indexed in Scilit: